TY - THES A1 - Schäfer, Christina T1 - Erich Welter - Der Mann hinter der F.A.Z. T1 - Erich Welter - The Man behind the F.A.Z. N2 - Wer war Erich Welter? Geboren 1900 in Straßburg, gelebt in Berlin, Frankfurt am Main und Mainz, gestorben 1982 in Frankfurt am Main. Sohn eines preußischen Beamten, Weltkriegsveteran des Ersten und Zweiten Weltkriegs, Wirtschaftsredakteur, wissenschaftlicher Autor, Politikberater, Professor für Volkswirtschaftslehre und Gründungsherausgeber der Frankfurter Allgemeinen Zeitung. Erich Welter war vieles, vor allem war er jedoch ein anpackender Unternehmer. Über 30 Jahre prägte er die Geschicke der F.A.Z. Sein Name findet sich mit der Betitelung Gründungsherausgeber bis heute im täglichen Impressum der F.A.Z., trotzdem ist er selbst langjährigen Lesern der Zeitung nicht geläufig. Erich Welter agierte nicht gerne im grellen Licht der Öffentlichkeit, er stand im Hintergrund. In der vorliegenden Biografie werden die vielfältigen Facetten des Mannes hinter der F.A.Z. verfolgt und in ihrer Gesamtheit beschrieben. N2 - Who was Erich Welter? Born 1900 in Strasbourg, lived in Berlin, Frankfurt on the Main and Mainz, died 1982 in Frankfurt on the Main. Son of a Prussian civil servant, veteran of the First and Second World War, economic editor, scientific author, political consultant, professor of economics and founding editor of the newspaper “Frankfurter Allgemeine Zeitung”. Erich Welter was many things, but above all he was a hands-on entrepreneur. He shaped the fate of the F.A.Z. for more than 30 years. His name is still to be found in the daily masthead of the F.A.Z. with the title "Gründungsherausgeber" (Founding Editor), but yet he is not familiar even to long-time readers of the newspaper. Erich Welter did not like to act in the limelight, he stood on the sideline. In this biography, the manifold facets of the man behind the F.A.Z. are traced and described in their entirety. KW - Welter, Erich KW - Frankfurter Allgemeine KW - Biografie KW - Frankfurter Allgemeine Zeitung GmbH KW - Johannes Gutenberg-Universität Mainz KW - Wirtschaftspolitische Gesellschaft von 1947 KW - Frankfurter Zeitung und Handelsblatt Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-192117 ET - 1. Auflage ER - TY - JOUR A1 - Donat, Ulrike A1 - Rother, Juliane A1 - Schäfer, Simon A1 - Hess, Michael A1 - Härtl, Barbara A1 - Kober, Christina A1 - Langbein-Laugwitz, Johanna A1 - Stritzker, Jochen A1 - Chen, Nanhai G. A1 - Aguilar, Richard J. A1 - Weibel, Stephanie A1 - Szalay, Alandar A. T1 - Characterization of Metastasis Formation and Virotherapy in the Human C33A Cervical Cancer Model JF - PLoS ONE N2 - More than 90% of cancer mortalities are due to cancer that has metastasized. Therefore, it is crucial to intensify research on metastasis formation and therapy. Here, we describe for the first time the metastasizing ability of the human cervical cancer cell line C33A in athymic nude mice after subcutaneous implantation of tumor cells. In this model, we demonstrated a steady progression of lumbar and renal lymph node metastases during tumor development. Besides predominantly occurring lymphatic metastases, we visualized the formation of hematogenous metastases utilizing red fluorescent protein (RFP) expressing C33A-RFP cells. RFP positive cancer cells were found migrating in blood vessels and forming micrometastases in lungs of tumor-bearing mice. Next, we set out to analyze the influence of oncolytic virotherapy in the C33A-RFP model and demonstrated an efficient virus-mediated reduction of tumor size and metastatic burden. These results suggest the C33A-RFP cervical cancer model as a new platform to analyze cancer metastases as well as to test novel treatment options to combat metastases. KW - metastasis KW - renal cancer KW - oncolytic viruses KW - lymph nodes KW - kidneys KW - lung and intrathoracic tumors KW - secondary lung tumors KW - cancer treatment Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-119674 SN - 1932-6203 VL - 9 IS - 6 ER - TY - JOUR A1 - Chopra, Martin A1 - Lang, Isabell A1 - Salzmann, Steffen A1 - Pachel, Christina A1 - Kraus, Sabrina A1 - Bäuerlein, Carina A. A1 - Brede, Christian A1 - Jordán Garrote, Ana-Laura A1 - Mattenheimer, Katharina A1 - Ritz, Miriam A1 - Schwinn, Stefanie A1 - Graf, Carolin A1 - Schäfer, Viktoria A1 - Frantz, Stefan A1 - Einsele, Hermann A1 - Wajant, Harald A1 - Beilhack, Andreas T1 - Tumor Necrosis Factor Induces Tumor Promoting and Anti-Tumoral Effects on Pancreatic Cancer via TNFR1 JF - PLoS ONE N2 - Multiple activities are ascribed to the cytokine tumor necrosis factor (TNF) in health and disease. In particular, TNF was shown to affect carcinogenesis in multiple ways. This cytokine acts via the activation of two cell surface receptors, TNFR1, which is associated with inflammation, and TNFR2, which was shown to cause anti-inflammatory signaling. We assessed the effects of TNF and its two receptors on the progression of pancreatic cancer by in vivo bioluminescence imaging in a syngeneic orthotopic tumor mouse model with Panc02 cells. Mice deficient for TNFR1 were unable to spontaneously reject Panc02 tumors and furthermore displayed enhanced tumor progression. In contrast, a fraction of wild type (37.5%), TNF deficient (12.5%), and TNFR2 deficient mice (22.2%) were able to fully reject the tumor within two weeks. Pancreatic tumors in TNFR1 deficient mice displayed increased vascular density, enhanced infiltration of CD4+ T cells and CD4+ forkhead box P3 (FoxP3)+ regulatory T cells (Treg) but reduced numbers of CD8+ T cells. These alterations were further accompanied by transcriptional upregulation of IL4. Thus, TNF and TNFR1 are required in pancreatic ductal carcinoma to ensure optimal CD8+ T cell-mediated immunosurveillance and tumor rejection. Exogenous systemic administration of human TNF, however, which only interacts with murine TNFR1, accelerated tumor progression. This suggests that TNFR1 has basically the capability in the Panc02 model to trigger pro-and anti-tumoral effects but the spatiotemporal availability of TNF seems to determine finally the overall outcome. KW - Bioluminescence KW - cancer treatment KW - cell staining KW - cytokines KW - immune cells KW - metastasis KW - regulatory T cells KW - T cells Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-97246 ER - TY - THES A1 - Schäfer, Christina T1 - Berechnung des Verhältnisses k der Mutationsraten von Spermatogenese zu Oogenese bei Muskeldystrophie Duchenne T1 - Considerations on different mutation rates in spermatogenesis and oogenesis in Duchenne muscular dystrophy N2 - Muskeldystrophie Duchenne (DMD) (Xp21.2) und gehört mit 1:3500 männlichen Geburten zu den häufigsten genetisch-determinierten Erkrankungen. DMD ist bis heute nicht heilbar. Die genetische Beratung ist Teil der Betreuung dieser Patienten und bezieht auch die heterozygotenwahrscheinlichkeit weiblicher Angehöriger mit ein. Für die Risikoberechnung zum Überträgerstatus weiblicher Angehöriger von DMD-Patienten sind neben Stammbauminformationen und Enzymwerten Verhältnisse der Mutationsraten ( k -Werte) essentiell, welche die unterschiedliche Entstehungswahrscheinlichkeit der einzelnen Mutationstypen (Deletion, Duplikation, Punktmutation) in Spermatogenese oder Oogenese beschreiben.Die Bestimmung des Verhältnisses k der Mutationsraten zeigte, dass einerseits Deletionen im Dystrophin-Gen viel häufiger großmütterlichen Ursprungs (k Deletion ≈ 0,26) und andererseits Punktmutationen im Dystrophin-Gen meist großväterlichen Ursprungs (k Punktmutation ≈ 2,8) sind. N2 - Duchenne muscular dystrophy (DMD) (X-linked recessive; Xp21.2) is one of the most common genetic disorders. Genetic counselling is an important part of medical care of these patients and their families. Carrier determination for Duchenne muscular dystrophy includes pedigree information and CK (Creatinkinase) - levels as well as male to female mutation rates depending on type of mutation (deletion, duplication and point mutation). Analysis of data from the Institute of Medical and Molecular Genetics showed that the vast majority of deletions are of grandmaternal origin (k deletion = 0,26) whereas point mutations rates are higher in spermatogenesis (k point mutation = 2,8). KW - Duchenne-Syndrom KW - Mutationsraten KW - Muskeldystrophie KW - Risikoberatung KW - Spermatogenese KW - Oogenese Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-109160 ER -